Pediatric Nephrology

, 26:2159 | Cite as

Cyclosporine A vs. methylprednisolone for Henoch–Schönlein nephritis: a randomized trial

  • Outi Jauhola
  • Jaana Ronkainen
  • Helena Autio-Harmainen
  • Olli Koskimies
  • Marja Ala-Houhala
  • Pekka Arikoski
  • Tuula Hölttä
  • Timo Jahnukainen
  • Jukka Rajantie
  • Timo Örmälä
  • Matti Nuutinen
Original Article


Knowledge about how to treat severe Henoch–Schönlein nephritis (HSN) is scarce. The aim of our study is to compare cyclosporine A (CyA) and methylprednisolone pulses (MP) in the treatment of severe HSN. Out of 24 pediatric HSN patients with nephrotic-range proteinuria or crescentic HSN in kidney biopsy, seven were randomized to receive CyA for 12 months at an initial dose of 5 mg/kg and eight to receive 3 MP pulses of 30 mg/kg followed by prednisone for 4 months. The other nine patients received identical treatment without randomization. Kidney biopsies were performed at inclusion and after 2 years. The primary outcomes were the duration of proteinuria and hematuria, estimated glomerular filtration rate, and renal biopsy histology. All the 11 CyA-treated patients achieved resolution of nephrotic-range proteinuria within 3 months, while the MP-group response was slower, and in 6/13 was not achieved with the initial treatment. Additional immunosuppressive treatment was needed in none of the CyA-treated patients but in six patients treated with MP (difference in proportion 46%, p = 0.008). The 2-year control biopsies were similarly improved in both groups. After mean 6.1 years (2.2–10.4 years), 16 patients (eight CyA, eight MP) had no renal symptoms and six (three CyA, three MP) had persistent nephropathy but normal renal function. One MP-treated patient had reduced renal function and another had developed ESRD and received a renal transplant. CyA gave a 100% resolution of nephrotic-range proteinuria and a 100% renal survival rate without additional therapy after a mean follow-up of 6 years. Treatment of HSN with CyA is efficacious, safe and not inferior to MP.


Vasculitis Glomerulonephritis Immunosuppressive treatment Proteinuria Hematuria Biopsy Outcome 



The following institutions and investigators participated in the study: Central Finland Central Hospital: A. Nuuja, Kainuu Central Hospital: P. Varimo, Lapland Central Hospital: R. Jauhola, Mikkeli Central Hospital: S. Kinnunen, North Karelia Central Hospital: J. Korhonen, Turku University Hospital: J. Kataja, and Åland Central Hospital: C. Johansson. We also thank Mr. Juha Turtinen, MSc for helping with the statistical analyses.

Statement of competing financial interests

The study was supported financially by the Alma and K. A. Snellman Foundation, Oulu, Finland, the Foundation for Pediatric Research, and the Finnish Kidney Foundation. None of the authors have any conflicts of interest.

Supplementary material

467_2011_1919_MOESM1_ESM.doc (73 kb)
Table S1 Clinical characteristics at enrollment and at the 2-year control visit (DOC 73 kb)


  1. 1.
    Calvino M, Llorca J, Garcia-Porrua C, Fernandez-Iglesias J, Rodriquez-Ledo P, Gonzalez-Gay M (2001) Henoch-Schönlein purpura in children from northwestern Spain: a 20-year epidemiologic and clinical study. Medicine 80:279–290PubMedCrossRefGoogle Scholar
  2. 2.
    Kaku Y, Nohara K, Honda S (1998) Renal involvement in Henoch–Schönlein purpura: a multivariate analysis of prognostic factors. Kidney Int 53:1755–1759PubMedCrossRefGoogle Scholar
  3. 3.
    Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch–Schönlein purpura: a retrospective cohort study. Lancet 360:666–670PubMedCrossRefGoogle Scholar
  4. 4.
    Jauhola O, Ronkainen J, Koskimies O, Ala-Houhala M, Arikoski P, Hölttä T, Jahnukainen T, Rajantie J, Örmälä T, Nuutinen M (2010) Clinical course of extrarenal symptoms in Henoch–Schönlein purpura: a 6-month prospective study. Arch Dis Child 95:871–876PubMedCrossRefGoogle Scholar
  5. 5.
    Narchi H (2005) Risk of long-term renal impairment and duration of follow-up recommended for Henoch–Schönlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 90:916–920PubMedCrossRefGoogle Scholar
  6. 6.
    Koskimies O, Rapola J, Savilahti E, Vilska J (1974) Renal involvement in Schönlein-Henoch purpura. Acta Pediatr Scand 63:357–363CrossRefGoogle Scholar
  7. 7.
    Stewart M, Savage J, Bell B, McCord B (1988) Long-term renal prognosis of Henoch–Schönlein purpura in an unselected childhood population. Eur J Pediatr 147:113–115PubMedCrossRefGoogle Scholar
  8. 8.
    Chartapisak W, Opastirakul S, Hodson E, Willis N, Craig J (2009) Interventions for preventing and treating kidney disease in Henoch–Schönlein purpura (HSP). Cochrane Database Syst Rev. Issue 3. Art. No.: CD005128. doi: 10.1002/14651858.CD005128.pub2
  9. 9.
    Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243PubMedCrossRefGoogle Scholar
  10. 10.
    Ronkainen J, Autio-Harmainen J, Nuutinen M (2003) Cyclosporin A for treatment of severe Henoch–Schönlein glomerulonephritis. Pediatr Nephrol 18:1138–1142PubMedCrossRefGoogle Scholar
  11. 11.
    Someya T, Kaneko K, Fujinaga S, Ohtaki R, Hira M, Yamashiro Y (2004) Cyclosporine A for heavy proteinuria in a child with Henoch–Schönlein purpura nephritis. Pediatr Int 46:111–113PubMedCrossRefGoogle Scholar
  12. 12.
    Shin J, Park J, Shin Y, Kim J, Kim P, Lee J, Jeong H (2005) Cyclosporin A therapy for severe Henoch–Schönlein nephritis with nephrotic syndrome. Pediatr Nephrol 20:1093–1097PubMedCrossRefGoogle Scholar
  13. 13.
    Shin J, Park J, Shin Y, Kim J, Lee J, Jeong H (2005) Henoch–Schönlein purpura nephritis with nephrotic-range proteinuria: histological regression possibly associated with cyclosporin A and steroid treatment. Scand J Rheumatol 34:392–395PubMedCrossRefGoogle Scholar
  14. 14.
    Park J, Won S, Shin J, Yim H, Pai K (2011) Cyclosporin A therapy for Henoch–Schönlein nephritis with nephrotic-range proteinuria. Pediatr Nephrol 26:411–417PubMedCrossRefGoogle Scholar
  15. 15.
    Huang D, Yang Y, Lin Y, Chiang B (2003) Cyclosporin A therapy for steroid-dependent Henoch–Schönlein purpura. J Microbiol Immunol Infect 36:61–64PubMedGoogle Scholar
  16. 16.
    Tarshish P, Bernstein J, Edelmann C (2004) Henoch–Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 19:51–56PubMedCrossRefGoogle Scholar
  17. 17.
    Ronkainen J, Koskimies O, Ala-Houhala M, Antikainen M, Merenmies J, Rajantie J, Örmälä T, Turtinen J, Nuutinen M (2006) Early prednisone therapy in Henoch–Schönlein purpura: a randomized, double-blind, placebo-controlled trial. J Pediatr 149:241–247PubMedCrossRefGoogle Scholar
  18. 18.
    Schwartz G, Brion L, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571–590PubMedGoogle Scholar
  19. 19.
    Counahan R, Winterborn M, White R, Heaton J, Meadow S, Bluett N, Swetschin H, Cameron J, Chantler C (1997) Prognosis of Henoch–Schönlein nephritis in children. BMJ 2:11–14CrossRefGoogle Scholar
  20. 20.
    Ronkainen J, Ala-Houhala M, Autio-Harmainen H, Jahnukainen T, Koskimies O, Merenmies J, Mustonen J, Örmälä T, Turtinen J, Nuutinen M (2006) Long-term outcome 19 years after childhood IgA nephritis: a retrospective cohort study. Pediatr Nephrol 9:1266–1273CrossRefGoogle Scholar
  21. 21.
    Antunes V, Veronese F, Morales J (2008) Diagnostic accuracy of the protein/creatinine ratio in urine samples to estimate 24-h proteinuria in patients with primary glomerulopathies: a longitudinal study. Nephrol Dial Transplant 23:2242–2246PubMedCrossRefGoogle Scholar
  22. 22.
    Ronkainen J, Ala-Houhala M, Huttunen N-P, Jahnukainen T, Koskimies O, Örmälä T, Nuutinen M (2003) Outcome of Henoch–Schönlein purpura with nephrotic-range proteinuria. Clin Nephrol 60:80–84PubMedGoogle Scholar
  23. 23.
    Samuels J, Strippoli G, Craig J, Schena F, Molony D (2003) Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. (4):CD003965Google Scholar
  24. 24.
    Levy G (2001) C2 monitoring strategy for optimising cyclosporine immunosuppression from the Neoral formulation. BioDrugs 15:279–290PubMedCrossRefGoogle Scholar
  25. 25.
    Ishikura K, Ikeda M, Hattori S, Yoshikawa N, Sasaki S, Iijima K, Nakanishi K, Yata N, Honda M (2008) Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial. Kidney Int 73:1167–1173PubMedCrossRefGoogle Scholar
  26. 26.
    Shin J, Park J, Lee J, Kim J, Kim P, Jeong H (2006) Successful use of cyclosporine A in severe Schönlein-Henoch nephritis resistant to both methylprednisolone pulse and azathioprine. Clin Rheumatol 25:759–760PubMedCrossRefGoogle Scholar
  27. 27.
    Faul C, Donnelly M, Merscher-Gomez S, Chang Y, Franz S, Delfgaauw J, Chang J, Choi H, Campbell K, Kim K, Reiser J, Mundel P (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931–938PubMedCrossRefGoogle Scholar
  28. 28.
    Hoyer P, Brodehl J, Ehrich J, Offner G (1991) Practical aspects in the use of cyclosporine in paediatric nephrology. Pediatr Nephrol 5:630–638PubMedCrossRefGoogle Scholar
  29. 29.
    Hamahira K, Iijima K, Tanaka R, Nakamura H, Yoshikawa N (2001) Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome. Pediatr Nephrol 16:723–727PubMedCrossRefGoogle Scholar
  30. 30.
    Pozzi C, Bolasco P, Fogazzi G, Andrulli S, Altieri P, Ponticelli C, Locatelli F (1999) Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet 353:883–887PubMedCrossRefGoogle Scholar
  31. 31.
    Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linne T (2007) IgACE: a placebo controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880–1888PubMedCrossRefGoogle Scholar
  32. 32.
    Algoet C, Proesmans W (2003) Renal biopsy 2–9 years after Henoch–Schönlein purpura. Pediatr Nephrol 18:471–473PubMedGoogle Scholar
  33. 33.
    Shin J, Park J, Shin Y, Kim J, Lee J, Kim P, Jeong H (2005) Can azathioprine and steroids alter the progression of severe Henoch–Schönlein nephritis in children? Pediatr Nephrol 20:1087–1092PubMedCrossRefGoogle Scholar
  34. 34.
    Niaudet P, Levy M, Broyer M, Habib R (1984) Clinicopathologic correlations in severe forms of Henoch–Schönlein purpura nephritis based on repeat biopsies. Contrib Nephrol 40:250–254PubMedGoogle Scholar

Copyright information

© IPNA 2011

Authors and Affiliations

  • Outi Jauhola
    • 1
  • Jaana Ronkainen
    • 2
  • Helena Autio-Harmainen
    • 3
  • Olli Koskimies
    • 4
  • Marja Ala-Houhala
    • 5
  • Pekka Arikoski
    • 6
  • Tuula Hölttä
    • 4
  • Timo Jahnukainen
    • 4
  • Jukka Rajantie
    • 7
  • Timo Örmälä
    • 8
  • Matti Nuutinen
    • 1
  1. 1.Department of Children and AdolescentsOulu University HospitalOuluFinland
  2. 2.Oulu City Health Care CentreOuluFinland
  3. 3.Department of PathologyOulu University HospitalOuluFinland
  4. 4.Hospital for Children and AdolescentsUniversity of HelsinkiHelsinkiFinland
  5. 5.Department of PediatricsTampere University HospitalTampereFinland
  6. 6.Department of PediatricsKuopio University HospitalKuopioFinland
  7. 7.Department of PediatricsHelsinki University Central Hospital, Jorvi HospitalEspooFinland
  8. 8.Department of PediatricsHyvinkää HospitalHyvinkääFinland

Personalised recommendations